BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 34448187)

  • 1. [A decade of checkpoint inhibitors: current standard of care and future trends].
    Reischer A; Kruger S; von Bergwelt-Baildon M
    Dtsch Med Wochenschr; 2021 Sep; 146(17):1108-1118. PubMed ID: 34448187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Therapies for Melanoma.
    Buchbinder EI
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):99-109. PubMed ID: 33759776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in melanoma.
    Carlino MS; Larkin J; Long GV
    Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions.
    Ralli M; Botticelli A; Visconti IC; Angeletti D; Fiore M; Marchetti P; Lambiase A; de Vincentiis M; Greco A
    J Immunol Res; 2020; 2020():9235638. PubMed ID: 32671117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.
    Usta SZ; Uchihashi T; Kodama S; Kurioka K; Inubushi T; Shimooka T; Sugauchi A; Seki S; Tanaka S
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conquering lung cancer: current status and prospects for the future.
    Pirker R
    Pulmonology; 2020; 26(5):283-290. PubMed ID: 32199906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for advanced melanoma: current situation in Japan.
    Kato J; Uhara H
    Jpn J Clin Oncol; 2021 Jan; 51(1):3-9. PubMed ID: 33140101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in immunotherapy for melanoma.
    Redman JM; Gibney GT; Atkins MB
    BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches.
    Kidwai N; Chen M; Postow MA; Hassel J; Callahan M
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432462. PubMed ID: 38768421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
    Hu ZI; Ho AY; McArthur HL
    Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in immunotherapy for metastatic melanoma].
    Oláh J
    Magy Onkol; 2017 Jun; 61(2):132-136. PubMed ID: 28585614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant immunotherapy for melanoma.
    Thomas D; Bello DM
    J Surg Oncol; 2021 Mar; 123(3):789-797. PubMed ID: 33595889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.
    Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C
    Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know.
    Chen M; Smith DA; Yoon JG; Vos D; Kikano EG; Tirumani SH; Ramaiya NH
    J Comput Assist Tomogr; 2022 Jul-Aug 01; 46(4):621-632. PubMed ID: 35675685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.